Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026

Haemonetics Corporation (NYSE: HAE), a prominent global medical technology firm, has announced that it will publish its financial results for the third quarter of fiscal year 2026 on February 5, 2026, at 6:00 AM ET. Following the release, the company has scheduled a conference call at 8:00 AM ET to discuss these results in detail with investors and analysts.

The conference call will provide an opportunity for participants to engage directly with the company’s leadership. Interested parties can join the call by registering in advance, which will provide them with a dial-in number and a personalized PIN. Although registration is not mandatory, attendees are encouraged to log in 10 minutes early to ensure prompt participation.

For those unable to attend the live event, Haemonetics will host a live webcast of the call, available through the company's investor relations website. A replay of the call will also be accessible for one year starting at 11:00 AM ET on the same day. This replay will offer those who missed the live discussion a chance to catch up on the insights and analyses shared during the conference.

Haemonetics is committed to improving healthcare quality and efficiency through innovative solutions. The company focuses on providing advanced hospital technologies, optimizing plasma collection operations, and enhancing blood component collection methods, illustrating its dedication to addressing critical medical needs and enhancing patient care outcomes.

For further information, investors can contact Olga Guyette, Vice President of Investor Relations, or David Trenk, Manager of Investor Relations. Media inquiries can be directed to Josh Gitelson, Sr. Director of Global Communications. For additional details, visit Haemonetics’ official website.

As Haemonetics Corporation (NYSE: HAE) gears up to publish its third quarter fiscal year 2026 results on February 5, 2026, investors should adopt a proactive approach to their positions in the company. The scheduled earnings report is crucial, as it provides insights into the company’s financial health, operational efficiency, and market response.

Investors should pay particular attention to revenue growth trends and profit margins, which are key indicators of the company’s operational performance. In the medical technology landscape, companies like Haemonetics, which focus on improving healthcare efficacy and efficiency, generally respond positively to favorable earnings reports. Given their focus on blood component collection and plasma technology, developments within the healthcare sector, regulatory changes, and advancements in technology will significantly influence their results.

Additionally, the accompanying conference call at 8:00 AM ET on the same day will be an opportunity for leadership to provide guidance on future growth and possibly disclose new product innovations or market expansions. Analysts will scrutinize these discussions, making the call vital for assessing market sentiment.

As the date approaches, it may be wise to position portfolios strategically. Investors should consider reviewing their holdings in Haemonetics, staying alert to any technical indicators leading up to the earnings announcement. Given the volatile nature of healthcare stocks, one might also consider employing stop-loss orders to protect against unexpected downturns, especially if there is a divergence between analyst expectations and actual results.

In conclusion, a well-rounded analysis of Haemonetics’ upcoming earnings report, market conditions, and investor sentiment will be essential for making informed investment decisions in the healthcare technology sector. Keeping an eye on the February 5 release can provide opportunities for both short-term trading strategies and long-term investments.